Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;39(10):1016-1027.
doi: 10.1016/j.healun.2020.07.009. Epub 2020 Jul 30.

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report - 2020; focus on deceased donor characteristics

Daniel C Chambers  1 , Andreas Zuckermann  1 , Wida S Cherikh  1 , Michael O Harhay  1 , Don Hayes Jr  1 , Eileen Hsich  1 , Kiran K Khush  1 , Luciano Potena  1 , Aparna Sadavarte  1 , Tajinder P Singh  1 , Josef Stehlik  2 ; International Society for Heart and Lung Transplantation  1
Affiliations
Review

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report - 2020; focus on deceased donor characteristics

Daniel C Chambers et al. J Heart Lung Transplant. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure statement Kiran Khush is supported by National Institutes of Health/National Heart, Lung, and Blood Institute award R01HL125303 to study evidence-based strategies for donor heart evaluation and serves as scientific adviser and speaker for CareDx, Inc. Luciano Potena serves as a speaker for Thermo Fisher, Sandoz, Abbott, and Novartis. Josef Stehlik is supported by American Heart Association grant 16SFRN31890003 to study patient health status in disease transitions and serves as consultant for Medtronic and Abbott. Daniel Chambers received research funding from Astellas and Boeringher-Ingelheim. Andreas Zuckermann serves on the speakers bureau of Paragonix, Mallinckrodt, and Franz Kohler Chemie. Eileen Hsich is supported by National Institutes of Health/National Heart, Lung, and Blood Institute award R01HL141892 to study disparities in survival among heart transplant candidates and recipients. The remaining authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Donor age, body mass index, and PO2 by year and region (transplants from eras as shown). (a) Age. (b) Body mass index. (c) PO2.
Figure 2
Figure 2
Donor cause of death by era and region (transplants: January 1992–June 2018). CVA, cerebrovascular accident.
Figure 3
Figure 3
Donor substance use by year (transplants from eras as shown). (a) Smoking. (b) Alcohol. (c) Cocaine. (d) Other.
Figure 4
Figure 4
Donor diabetes and hypertension by year (transplants: January 1995–June 2018). (a) Diabetes. (b) Hypertension.
Figure 5
Figure 5
Kaplan–Meier survival for adult lung transplant recipients by donor age (transplants: January 2000–June 2017 and January 2000–June 2013, respectively). (a) 12 months. (b) 5 years conditional on survival to 1 year. NS, not significant.
Figure 6
Figure 6
Kaplan–Meier survival within 12 months for adult lung transplant recipients by donor and recipient age (transplants: January 2000–June 2017). NS, not significant.
Figure 7
Figure 7
Kaplan–Meier survival for adult lung transplant recipients by donor cause of death (transplants: January 2000–June 2017 and January 2000–June 2013, respectively). (a) 12 months. (b) 5 years conditional on survival to 1 year. CVA, cerebrovascular accident; NS, not significant.
Figure 8
Figure 8
Kaplan–Meier survival for adult lung transplant recipients by donor PO2 (transplants: January 2005–June 2017 and January 2005–June 2013, respectively). (a) 12 months. (b) 5 years conditional on survival to 1 year. NS, not significant.
Figure 9
Figure 9
Kaplan–Meier survival within 12 months for adult lung transplant recipients by donor substance use (transplants from eras as shown). (a) Smoking. (b) Alcohol. (c) Cocaine. (d) Other. NS, not significant.
Figure 10
Figure 10
Kaplan–Meier survival within 5 years conditional on survival to 1 year for adult lung transplant recipients by donor substance use (transplants from eras as shown). (a) Smoking. (b) Alcohol. (c) Cocaine. (d) Other.
Figure 11
Figure 11
Kaplan–Meier survival for adult lung transplant recipients by donor diabetes (transplants from eras as shown). (a) 12 months. (b) 5 years conditional on survival to 1 year.
Figure 12
Figure 12
Kaplan–Meier survival for adult lung transplant recipients by donor hypertension (transplants: January 2000–June 2017 and January 2000–June 2013, respectively). (a) 12 months. (b) 5 years conditional on survival to 1 year.
Figure 13
Figure 13
Kaplan–Meier survival within 5 years conditional on survival to 1 year for adult lung transplant recipients by donor history of hypertension and ischemic time (transplants: January 2005–June 2013).
Figure 14
Figure 14
Kaplan–Meier freedom from BOS conditional on survival to discharge for adult lung transplant recipients by donor age (transplants: January 2000–June 2017). BOS, bronchiolitis obliterans syndrome.
Figure 15
Figure 15
Kaplan–Meier freedom from BOS conditional on survival to discharge for adult lung transplant recipients by donor substance use (transplants from eras as shown). (a) Smoking. (b) Alcohol. (c) Cocaine. (d) Other. BOS, bronchiolitis obliterans syndrome; NS, not significant.
Figure 16
Figure 16
Kaplan–Meier freedom from BOS conditional on survival to discharge for adult lung transplant recipients by donor diabetes and hypertension (transplants from January 2000 to June 2017). (a) Diabetes. (b) Hypertension. BOS, bronchiolitis obliterans syndrome; NS, not significant.
See this image and copyright information in PMC

References

    1. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant 2018;37:1169–83. - PubMed
    1. Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38:1042–55. - PMC - PubMed
    1. Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017;36:1047–59. - PubMed
    1. Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report—2013; focus theme: age. J Heart Lung Transplant 2013;32:965–78. - PubMed
    1. Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 2016;35:1170–84. - PubMed

Publication types

MeSH terms